Verteporfin Therapy of Subfoveal Occult Choroidal Neovascularization in AMD Using Delayed Light Application: One-year Results of the VALIO Study
- 31 December 2007
- journal article
- research article
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 144 (6) , 970-972.e4
- https://doi.org/10.1016/j.ajo.2007.08.017
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1American Journal of Ophthalmology, 2003
- Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy report 2American Journal of Ophthalmology, 2001
- Photodynamic Therapy With Verteporfin for Choroidal Neovascularization Caused by Age-related Macular DegenerationArchives of Ophthalmology (1950), 1999
- Photodynamic Therapy With Verteporfin for Choroidal Neovascularization Caused by Age-related Macular DegenerationArchives of Ophthalmology (1950), 1999